III-话题@MedSci

#III#

818篇内容 | 2523人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1916518, encodeId=55031916518f5, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, objectType=article, longId=295346, objectId=6f04295346b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f04295346b6, replyNumber=0, likeNumber=64, createdTime=2022-04-17, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f04295346b6, moduleTitle=Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f04295346b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916533, encodeId=58e219165335d, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, objectType=article, longId=301718, objectId=f3b0301e18e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3b0301e18e1, replyNumber=0, likeNumber=93, createdTime=2022-10-11, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3b0301e18e1, moduleTitle=ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3b0301e18e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916538, encodeId=7aeb1916538c8, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, objectType=article, longId=302279, objectId=6eee3022e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eee3022e979, replyNumber=0, likeNumber=96, createdTime=2023-01-27, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eee3022e979, moduleTitle=度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eee3022e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916539, encodeId=9332191653981, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, objectType=article, longId=302280, objectId=14b430228084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14b430228084, replyNumber=0, likeNumber=0, createdTime=2023-03-05, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14b430228084, moduleTitle=Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14b430228084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916521, encodeId=ace8191652136, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, objectType=article, longId=295703, objectId=ea9c295e0337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea9c295e0337, replyNumber=0, likeNumber=74, createdTime=2022-05-27, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea9c295e0337, moduleTitle=Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea9c295e0337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916528, encodeId=a3441916528bb, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, objectType=article, longId=300860, objectId=e92c300860d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92c300860d9, replyNumber=0, likeNumber=181, createdTime=2022-11-10, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92c300860d9, moduleTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92c300860d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916536, encodeId=d2fb191653650, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, objectType=article, longId=302277, objectId=26843022e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26843022e794, replyNumber=0, likeNumber=122, createdTime=2022-04-29, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26843022e794, moduleTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26843022e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916530, encodeId=023519165309b, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, objectType=article, longId=300931, objectId=f500300931ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f500300931ea, replyNumber=0, likeNumber=92, createdTime=2022-05-01, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f500300931ea, moduleTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f500300931ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916525, encodeId=f7a019165254a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Cancer Commun：国内多中心III期研究EXELOX表明XELOX和EOX方案一线治疗晚期胃癌疗效相当, objectType=article, longId=300056, objectId=2c9b300056a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2c9b300056a4, replyNumber=0, likeNumber=109, createdTime=2022-08-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2c9b300056a4, moduleTitle=Cancer Commun：国内多中心III期研究EXELOX表明XELOX和EOX方案一线治疗晚期胃癌疗效相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2c9b300056a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916522, encodeId=ddb9191652227, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=亚太III期BHV3000-310研究显示，口服降钙素基因相关肽（CGRP）受体拮抗剂，可快速和持久地缓解偏头痛, objectType=article, longId=295705, objectId=74b3295e05cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74b3295e05cf, replyNumber=0, likeNumber=89, createdTime=2022-05-13, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74b3295e05cf, moduleTitle=亚太III期BHV3000-310研究显示，口服降钙素基因相关肽（CGRP）受体拮抗剂，可快速和持久地缓解偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74b3295e05cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916562, encodeId=a57019165626a, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=AP&T: I、III和IV型胶原蛋白相关的血清学标志物与狭窄性和穿透性克罗恩病疾病进展有关, objectType=article, longId=735600, objectId=ea54e3560061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea54e3560061, replyNumber=0, likeNumber=96, createdTime=2022-08-12, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea54e3560061, moduleTitle=AP&T: I、III和IV型胶原蛋白相关的血清学标志物与狭窄性和穿透性克罗恩病疾病进展有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea54e3560061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916509, encodeId=ce95191650988, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, objectType=article, longId=292042, objectId=cf0429204269, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf0429204269, replyNumber=0, likeNumber=68, createdTime=2022-07-23, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf0429204269, moduleTitle=新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf0429204269)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916554, encodeId=352a191655413, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=喜讯 | 梅斯医学服务复星杏脉肺结节CT影像辅助检测III类医疗器械AI产品成功获批上市, objectType=article, longId=727904, objectId=c91be2790430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c91be2790430, replyNumber=0, likeNumber=146, createdTime=2022-12-08, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c91be2790430, moduleTitle=喜讯 | 梅斯医学服务复星杏脉肺结节CT影像辅助检测III类医疗器械AI产品成功获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c91be2790430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916561, encodeId=b73c191656135, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, objectType=article, longId=735666, objectId=d837e3566673, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d837e3566673, replyNumber=0, likeNumber=102, createdTime=2022-09-11, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d837e3566673, moduleTitle=惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d837e3566673)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916506, encodeId=dab21916506fa, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效, objectType=article, longId=264985, objectId=1e88264985e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e88264985e4, replyNumber=0, likeNumber=87, createdTime=2022-09-29, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e88264985e4, moduleTitle=Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1e88264985e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916512, encodeId=78a2191651258, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性, objectType=article, longId=293627, objectId=c7ac29362eb8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7ac29362eb8, replyNumber=0, likeNumber=76, createdTime=2022-07-14, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7ac29362eb8, moduleTitle=Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7ac29362eb8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916535, encodeId=632c191653563, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=ASCO指南更新！I-IIIA期肺癌术后辅助治疗推荐, objectType=article, longId=302134, objectId=5d9d3021340f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d9d3021340f, replyNumber=0, likeNumber=74, createdTime=2022-10-29, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d9d3021340f, moduleTitle=ASCO指南更新！I-IIIA期肺癌术后辅助治疗推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d9d3021340f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916502, encodeId=99cf191650247, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, objectType=article, longId=220997, objectId=b57822099e0a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57822099e0a, replyNumber=0, likeNumber=82, createdTime=2021-12-06, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57822099e0a, moduleTitle=Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57822099e0a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916492, encodeId=1e83191649202, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=柳叶刀发表FAVOR III China研究结果，中国原创QFR指导冠脉PCI可降低35%术后风险, objectType=article, longId=219983, objectId=b17f219983ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b17f219983ac, replyNumber=0, likeNumber=82, createdTime=2022-09-09, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b17f219983ac, moduleTitle=柳叶刀发表FAVOR III China研究结果，中国原创QFR指导冠脉PCI可降低35%术后风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b17f219983ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1916514, encodeId=150c191651496, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, objectTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, objectType=article, longId=294057, objectId=20b829405e40, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b829405e40, replyNumber=0, likeNumber=77, createdTime=2022-09-28, rootId=0, userName=juliusluan78, userId=e68e415, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b829405e40, moduleTitle=J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20b829405e40)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III

2020-05-29

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Clin Cancer Res: Olaparib(奥拉帕利)单药维持治疗亚洲人群铂敏感复发卵巢癌的疗效：III期临床研究L-MOCA

2022-04-17

juliusluan78 (审核中...)

前往app查看评论内容

#III#

ESMO：阿替利珠单抗辅助治疗可以减少II-IIIA期NSCLC术后复发风险（IMpower010研究）

2022-10-11

juliusluan78 (审核中...)

前往app查看评论内容

#III#

度伐利尤单抗治疗局部晚期宫颈癌III期研究，结果失败

2023-01-27

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Keytruda联合PARP抑制剂III期临床试验失败！默沙东终止研究

2023-03-05

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Ann Oncol：III期BROCADE3研究表明Veliparib（维利帕尼）联合卡铂/紫杉醇后Veliparib维持治疗可改善BRCA1/2生殖系突变乳腺癌患者的疗效

2022-05-27

juliusluan78 (审核中...)

前往app查看评论内容

#III#

J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案

2022-11-10

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）

2022-04-29

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当

2022-05-01

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Cancer Commun：国内多中心III期研究EXELOX表明XELOX和EOX方案一线治疗晚期胃癌疗效相当

2022-08-09

juliusluan78 (审核中...)

前往app查看评论内容

#III#

亚太III期BHV3000-310研究显示，口服降钙素基因相关肽（CGRP）受体拮抗剂，可快速和持久地缓解偏头痛

2022-05-13

juliusluan78 (审核中...)

前往app查看评论内容

#III#

AP&T: I、III和IV型胶原蛋白相关的血清学标志物与狭窄性和穿透性克罗恩病疾病进展有关

2022-08-12

juliusluan78 (审核中...)

前往app查看评论内容

#III#

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌：全球III期试验已经开始

2022-07-23

juliusluan78 (审核中...)

前往app查看评论内容

#III#

喜讯 | 梅斯医学服务复星杏脉肺结节CT影像辅助检测III类医疗器械AI产品成功获批上市

2022-12-08

juliusluan78 (审核中...)

前往app查看评论内容

#III#

惊艳亮相！NADIM II：新辅助化免联合为可切除IIIA/B期NSCLC带来生存获益！| WCLC 2022速递

2022-09-11

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Front Oncol：IIIA/N2非小细胞肺癌（NSCLC）患者肺叶切除术对比肺亚叶切除术的疗效

2022-09-29

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Gastric Cancer：III期TAGS研究不同年龄亚组分析Trifluridine and tipiracil (曲氟尿苷替匹嘧啶，FTD/TPI)治疗经治转移性胃/胃食管交界处癌(mGC/GEJC)患者的疗效和安全性

2022-07-14

juliusluan78 (审核中...)

前往app查看评论内容

#III#

ASCO指南更新！I-IIIA期肺癌术后辅助治疗推荐

2022-10-29

juliusluan78 (审核中...)

前往app查看评论内容

#III#

Thorac Cancer： EGFR-TKIs提前应用可改善不可切除的III期EGFR突变肺腺癌的预后

2021-12-06

juliusluan78 (审核中...)

前往app查看评论内容

#III#

柳叶刀发表FAVOR III China研究结果，中国原创QFR指导冠脉PCI可降低35%术后风险

2022-09-09

juliusluan78 (审核中...)

前往app查看评论内容

#III#

J Clin Oncol：III期临床研究评估PD-1抑制剂Spartalizumab 联合Dabrafenib（达拉非尼）+ Trametinib（曲美替尼）治疗BRAF V600突变不可切除或转移性黑色素瘤的疗效

2022-09-28

科室
- - 订阅+
  - 更多科室
工具
服务